

Title (en)
TREATMENT OF T-CELL MEDIATED DISEASES

Title (de)
BEHANDLUNG VON T-ZELL-VERMITTELTEN KRANKHEITEN

Title (fr)
TRAITEMENT DE MALADIES A MEDIATION DES LYMPHOCYTES T

Publication
EP 1622633 A4 20100217 (EN)

Application
EP 04752368 A 20040514

Priority
• US 2004015340 W 20040514
• US 47101703 P 20030515
• US 48927003 P 20030721
• US 51493003 P 20031027
• US 51733803 P 20031104

Abstract (en)
[origin: WO2004103304A2] The invention provides a method of treating T-cell mediated diseases and a method of inhibiting the activation of T-cells using certain diketopiperazines. The invention also provides methods of synthesizing diketopiperazines and pharmaceutical compositions comprising certain diketopiperazines. The invention further provides methods of making improved pharmaceutical compositions of proteins and peptides by either increasing or decreasing the content of diketopiperazines in the compositions and the resultant improved pharmaceutical compositions.

IPC 8 full level
A61K 38/00 (2006.01); **A61K 31/495** (2006.01); **A61K 31/496** (2006.01); **A61P 37/06** (2006.01)

IPC 8 main group level
A61K (2006.01)

CPC (source: EP KR US)
A61K 9/00 (2013.01 - US); **A61K 9/0048** (2013.01 - US); **A61K 9/20** (2013.01 - KR); **A61K 9/48** (2013.01 - KR);
A61K 31/495 (2013.01 - EP KR US); **A61K 31/4965** (2013.01 - KR); **A61K 38/12** (2013.01 - EP US); **A61K 45/06** (2013.01 - EP US);
A61P 1/00 (2017.12 - EP); **A61P 1/04** (2017.12 - EP); **A61P 1/16** (2017.12 - EP); **A61P 1/18** (2017.12 - EP); **A61P 3/10** (2017.12 - EP);
A61P 5/14 (2017.12 - EP); **A61P 5/38** (2017.12 - EP); **A61P 5/50** (2017.12 - EP); **A61P 7/06** (2017.12 - EP); **A61P 9/10** (2017.12 - EP);
A61P 11/00 (2017.12 - EP US); **A61P 13/00** (2017.12 - EP); **A61P 13/12** (2017.12 - EP); **A61P 17/00** (2017.12 - EP); **A61P 17/06** (2017.12 - EP);
A61P 19/02 (2017.12 - EP); **A61P 19/04** (2017.12 - EP); **A61P 21/00** (2017.12 - EP); **A61P 21/04** (2017.12 - EP); **A61P 25/00** (2017.12 - EP);
A61P 25/02 (2017.12 - EP); **A61P 27/02** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 37/00** (2017.12 - EP);
A61P 37/02 (2017.12 - EP); **A61P 37/06** (2017.12 - EP); **A61P 37/08** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07D 241/08** (2013.01 - EP US)

Citation (search report)
• [X] US 2002052381 A1 20020502 - BAR-OR DAVID [US], et al
• [X] CS 254868 B1 19880215 - VANZURA JIRI [CS], et al
• [X] WO 9503054 A1 19950202 - LXR BIOTECHNOLOGY INC [US], et al
• [X] WO 02083667 A2 20021024 - VERTEX PHARMA [US], et al
• [X] RAINBOW T C ET AL: "Distribution, survival and biological effects in mice of a behaviorally active, enzymatically stable peptide: Pharmacokinetics of cyclo(Leu-Gly) and puromycin-induced amnesia", PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, ELSEVIER, US, vol. 10, no. 5, 1 May 1979 (1979-05-01), pages 787 - 793, XP023807330, ISSN: 0091-3057, [retrieved on 19790501]
• See references of WO 2004103304A2

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)
WO 2004103304 A2 20041202; WO 2004103304 A3 20050707; AU 2004241101 A1 20041202; AU 2004241101 B2 20100513;
AU 2010203293 A1 20100812; AU 2010203293 B2 20140109; CA 2523467 A1 20041202; CA 2523467 C 20211026; CA 3050734 A1 20041202;
CN 101947306 A 20110119; CN 101947306 B 20140618; CN 102210852 A 20111012; CN 102210852 B 20161019; CN 102727861 A 20121017;
CN 102727861 B 20150513; CN 103142599 A 20130612; CN 103191409 A 20130710; CN 103191410 A 20130710; CN 103191410 B 20150304;
CN 104095851 A 20141015; DK 2537524 T3 20161024; EP 1622633 A2 20060208; EP 1622633 A4 20100217; EP 1622633 B1 20160224;
EP 2517718 A2 20121031; EP 2517718 A3 20130403; EP 2517718 B1 20160302; EP 2517719 A1 20121031; EP 2517719 B1 20160330;
EP 2517721 A2 20121031; EP 2517721 A3 20130410; EP 2517722 A2 20121031; EP 2517722 A3 20130424; EP 2517722 B1 20160302;
EP 2537524 A2 20121226; EP 2537524 A3 20130327; EP 2537524 B1 20160706; EP 2799114 A2 20141105; EP 2799114 A3 20150218;
ES 2572454 T3 20160531; ES 2572975 T3 20160603; ES 2575563 T3 20160629; ES 2579635 T3 20160812; ES 2596180 T3 20170105;
HK 1148690 A1 20110916; HK 1173394 A1 20130516; HK 1173669 A1 20130524; HK 1178427 A1 20130913; HK 1178810 A1 20130919;
HK 1203056 A1 20151016; HK 1203164 A1 20151023; HU E031620 T2 20170728; IL 171961 A0 20060410; IL 171961 A 20140227;
IL 230815 A0 20140331; IL 230815 A 20171130; IL 231142 A0 20140331; IL 231142 A 20161031; JP 2007500747 A 20070118;
JP 2011102309 A 20110526; JP 2014167014 A 20140911; JP 6102822 B2 20170329; KR 20060022659 A 20060310;
KR 20120091266 A 20120817; KR 20120101164 A 20120912; KR 20150080004 A 20150708; KR 20170038128 A 20170405;
NZ 542886 A 20090626; NZ 576931 A 20101224; PL 2537524 T3 20170131; PT 2537524 T 20160905; US 10828296 B2 20201110;
US 11369598 B2 20220628; US 2005119177 A1 20050602; US 2010143338 A1 20100610; US 2010144611 A1 20100610;
US 2010190696 A1 20100729; US 2012022004 A1 20120126; US 2013065839 A1 20130314; US 2013071436 A1 20130321;
US 2013071448 A1 20130321; US 2013072684 A1 20130321; US 2013079284 A1 20130328; US 2016015705 A1 20160121;
US 2018140598 A1 20180524; US 2020030321 A1 20200130; US 2021121457 A1 20210429; US 2022288062 A1 20220915;
US 7732403 B2 20100608; US 8183209 B2 20120522; US 8324167 B2 20121204; US 8513196 B2 20130820; US 8551953 B2 20131008;
US 8962568 B2 20150224; US 8969308 B2 20150303; US 9707227 B2 20170718; US 9730924 B2 20170815

DOCDB simple family (application)
US 2004015340 W 20040514; AU 2004241101 A 20040514; AU 2010203293 A 20100723; CA 2523467 A 20040514; CA 3050734 A 20040514;
CN 201010193231 A 20040514; CN 201110147118 A 20040514; CN 201210242001 A 20040514; CN 201310049207 A 20040514;
CN 201310049222 A 20040514; CN 201310049225 A 20040514; CN 201410280192 A 20040514; DK 12005456 T 20040514;

EP 04752368 A 20040514; EP 12005454 A 20040514; EP 12005455 A 20040514; EP 12005456 A 20040514; EP 12005457 A 20040514;
EP 12005458 A 20040514; EP 14175385 A 20040514; ES 04752368 T 20040514; ES 12005455 T 20040514; ES 12005456 T 20040514;
ES 12005457 T 20040514; ES 12005458 T 20040514; HK 11102919 A 20110323; HK 13100888 A 20130121; HK 13100889 A 20130121;
HK 13105257 A 20130430; HK 13106497 A 20130603; HK 15103600 A 20150414; HK 15103642 A 20150415; HU E12005456 A 20040514;
IL 17196105 A 20051114; IL 23081514 A 20140204; IL 23114214 A 20140225; JP 2006533125 A 20040514; JP 2010292763 A 20101228;
JP 2014093779 A 20140430; KR 20057021755 A 20051115; KR 20127014047 A 20040514; KR 20127020086 A 20040514;
KR 20157016536 A 20040514; KR 20177008646 A 20040514; NZ 54288604 A 20040514; NZ 57693104 A 20040514; PL 12005456 T 20040514;
PT 12005456 T 20040514; US 201113247782 A 20110928; US 201213676932 A 20121114; US 201213676966 A 20121114;
US 201213676984 A 20121114; US 201213677007 A 20121114; US 201213679599 A 20121116; US 201514636650 A 20150303;
US 201715642707 A 20170706; US 201916591322 A 20191002; US 202017060750 A 20201001; US 202217751220 A 20220523;
US 70794210 A 20100218; US 70795810 A 20100218; US 75367110 A 20100402; US 84648204 A 20040514